Parameters of hemostatic potential in various stages of bladder cancer

A. Vasylaki, V. Dmytryk, T. Luhovska, P. Yakovlev
ESC "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv, Kyiv, Ukraine; ESC "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv, Kyiv, Ukraine; ESC "Institute of Biology and Medicine", Taras Shevchenko National University of Kyiv, Kyiv, Ukraine; O. Bogomolets National Medical University, Kyiv

Abstract


Bladder cancer is characterized by a high mortality rate and is the 9th most common cancerous disease in the world. With a wide array of diagnostic bases, which include cystoscopy, ultrasound, computer and magnetic resonance imaging, cytology of urine deposition, it is difficult to accurately determine the extent of development of the tumor. It is important to find molecular and biochemical predictive parameters that would be characterized by high specificity and sensitivity to the tumor development. According to modern scientific data, an imbalance in the coagulation system is observed in cancer patients, the manifestation of which is the activation of the blood clotting system. Activation of the hemostatic system is accompanied by the appearance in the bloodstream of specific markers that reflect increase the hemostatic potential of the blood, such as the level of fibrin, fibrinogen, prothrombin time, activated partial thromboplastin time, activated plasma recalcification time. The results of a study of various cancers indicate an increased level of components of the plasminogen activation system, including the inhibitor of plasminogen activator-1 (PAI-1). The literature data that would indicate the prognostic significance of changes in the parameters of the blood clotting system and the proteolytic system in the blood in bladder cancer are few and have not completed. There are no data indicating the link between the studied parameters with histopathological gradation. In a detailed review of markers, it is possible to identify the optimal combination of markers of pathological processes, including the pathogenesis of oncological processes at various stages. During the study, we have investigated a significant increase in the level of fibrin, fibrinogen, and PAI-1, depending on the degree of bladder cancer. The test scores can make a significant contribution to the characterization of bladder cancer, depending on the grade according to the histopathological classification.

Keywords


bladder cancer, hemostasis, fibrin, fibrinogen, PAI-1

Full Text:

PDF>PDF

References


Agnelii G. Venous thromboembolism and cancer: two-way clinicalassociation. Agnelii G, et al. Thromb. Haemost. 1997;78, N 1:117–120.

Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion andvascularization. Nat Med. 1998;4:923-928.

Becker M, Tilki D, Szarvas T, Rubben H, Ergun S. Urine based markers of angiogenesis in bladder cancer. Urologe A.2009;48:609-614.

Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002;26:767-771.

Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit. Rev. Oncol. Hematol. 2004; 50.3:187–196

Duffy MJ, Maguire TM, McDermott EW, O'Higgins N.Urokinase plasminogen activator: a prognostic marker inmultiple types of cancer. J SurgOncol. 1999;71:130-135.

Ghezzi LM, et al. Prognostic significance of preoperative plasma fibrinogen in endometrial cancer Gynecol.Oncol. 2010;119: 309–313.

Gontero P, Banisadr S, Frea B, Brausi M. Metastasismarkers in bladder cancer: a review of the literature andclinical considerations. Eur Urol. 2004;46:296-311.

Harbeck N, Kates RE, Gauger K, et al. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. ThrombHaemost. 2004;91:450-456.

Ikushima, S., R. Ono, K. Fukuda, et al. Trousseau's syndrome: cancer-associated thrombosis. Jpn. J. Clin. Oncol. 2016; 46: 204–208.

Ishchuk T, Glavachek D, Savchuk O, Yakovlev P, Falaleeva T, Beregova T, Ostapchenko L. (2018). Plasma levels of MMPs and TIMP-1 in urinary bladder cancer patients. Biomedical Research and Therapy. 5. 1931-1940. 10.15419/bmrat.v5i1.407.

Jones JM, et al. Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006; 53:97–101

Kakkar, A.K., Levine M.N. Thrombosis and cancer: implications beyond Trousseau. Journal of Thrombosis and Haemostasis. 2004; 8: 1261–1262.

Kwaan HC, Wang J, Svoboda K, Declerck PJ. Plasminogenactivator inhibitor 1 may promote tumour growth throughinhibition of apoptosis. Br J Cancer. 2000;82:1702-1708.

Lademann UA, Romer MU. Regulation of programmed celldeath by plasminogen activator inhibitor type 1 (PAI-1).ThrombHaemost. 2008;100:1041-1046.

Lee JH, et al. Preoperative plasma fibrinogen levels in gastric cancer patients correlate with extent of tumour. Hepatogastroenterology. 2004; 51: 1860–1863

Lima, L.G. & R.Q. Monteiro. 2013. Activation of blood coagulation in cancer: implications for tumour progression.Biosci.Rep.33. https://doi.org/ 10.1042/BSR20130057

Loreto M. F., Martinis D. E., Corsi M. P. Coagulation and cancer:implications for diagnosis and management. Pathol. Oncol. Res.2000; 6:302–312.

Mackman, N., R.E. Tilley & N.S. Key. 2007. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler. Thromb. Vasc. Biol. 27: 1687-1693.

Palmieri D, Lee JW, Juliano RL, Church FC. Plasminogenactivator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 B breast cancer cells. J Biol Chem.2002;277:40950-40957

Palta, S., R. Saroa& A. Palta. 2014. Overview of the coagulation system. Indian J. Anaesth. 58: 515–523.

Palumbo JS, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000; 96:3302–3309

Prandoni P., Piccioli A., Girolami A. Cancer and venous thromboembolism: an overview. Hematologica. 1999; 84: 437–445.

RaetskaYa& M. Chornenka, N & V. Koval, T & M Savchuk, O &Beregova, T & I. Ostapchenko, L. (2017). Cytokine profile indicators in rat blood serum in a model of esophagus burn induced by antioxidant chemical preparation. Biomedical Research and Therapy. 4. 1591. 10.15419/bmrat. v4i9.367.

Repetto, Ombretta& De Re, Valli. (2017). Coagulation and fibrinolysis in gastric cancer. Annals of the New York Academy of Sciences. 1404. 10.1111/nyas.13454.

Rice K.R., Brassell S.A., McLeod D.G. Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment //Reviews in urology. – 2010. – V.12. – P.111-24.

Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. BaillieresClinHaematol. 1995;8:291-312.

Schmitt M, Harbeck N, Thomssen C, et al. Clinical impactof the plasminogen activation system in tumor invasion andmetastasis: prognostic relevance and target for therapy.ThrombHaemost. 1997;78:285-296.

Seebacher V, et al. The prognostic value of pasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. BritishJournalofCancer. 2010; 102: 952–956.

Shariat SF, Monoski MA, Andrews B, et al: Association of plasma urokinase-type plasmino gen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003; 61: 1053-1058.

Span PN, Witjes JA, Grebenchtchikov N, et al. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison betweennormal and matched cancerous tissues. BJU Int.2008;102:177-182. 32. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activationsystem. Int J Cancer. 1997;71:116-122.

Von Tempelhoff GF, et al. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy. Clin. Hemorheol. Microcirc. 2000;22:107–130.

Received in the editorial: 10.09.2018

Received a revised version: 15.10.2018

Signed in the press: 15.10.2018


Refbacks

  • There are currently no refbacks.


Лицензия Creative Commons
This journal is available according to the Creative Commons License «Attribution» («Атрибуція») 4.0 Global (CC-BY).